Trigyn Technologies Secures Approval for 4.5 Lakh Equity Shares Under ESOP 2025
Trigyn Technologies Limited (TTL) received approval from NSE and BSE to list 4,50,000 equity shares under its Employee Stock Option Plan 2025. The approval is subject to compliance with SEBI regulations and other conditions. However, TTL's Q1 FY2025-26 financial results show a decline, with consolidated revenue dropping to ₹22,450.00 lakhs and a net loss of ₹460.86 lakhs. The company also faces challenges including arbitration proceedings with NMSCDCL and a GST department notice for ₹9.08 crores. On the positive side, TTL approved new roles for an executive and received approval to incorporate a subsidiary in Dubai.

*this image is generated using AI for illustrative purposes only.
Trigyn Technologies Limited (TTL) has received a significant boost to its employee stock option plan, as the company announced in-principle approval from both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) for listing up to 4,50,000 equity shares under its Employee Stock Option Plan 2025.
Exchange Approval Details
The approval letters, issued on August 12, 2025, bear the reference numbers NSE/LIST/49438 and DCS/AMAL/RG/IP/3741/2025-26 for NSE and BSE respectively. This move allows TTL to allot equity shares to employees upon the exercise of their stock options, subject to various listing conditions.
Conditions for Approval
The exchanges have stipulated several conditions for the approval, including:
- Compliance with SEBI regulations
- Receipt of necessary statutory approvals
- Submission of required documentation
It's important to note that the exchanges reserve the right to withdraw approval if the submitted information is found to be incomplete or misleading.
Financial Performance
While the ESOP approval marks a positive development for Trigyn Technologies, the company's recent financial results present a mixed picture:
Consolidated Results
| Particulars | Q1 FY2025-26 (₹ in Lakhs) | Q1 FY2024-25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 22,450.00 | 24,194.44 |
| Total Income | 22,894.00 | 24,618.50 |
| Net Profit/(Loss) | (460.86) | 761.38 |
The company reported a consolidated revenue from operations of ₹22,450.00 lakhs, down from ₹24,194.44 lakhs in the same quarter of the previous year. More notably, Trigyn Technologies recorded a net loss of ₹460.86 lakhs, compared to a net profit of ₹761.38 lakhs in the corresponding quarter.
Standalone Results
| Particulars | Q1 FY2025-26 (₹ in Lakhs) | Q1 FY2024-25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 3,541.02 | 3,667.47 |
| Total Income | 3,610.66 | 3,718.40 |
| Net Profit/(Loss) | (499.02) | (371.45) |
On a standalone basis, the company's performance also showed a decline. Revenue from operations decreased to ₹3,541.02 lakhs from ₹3,667.47 lakhs in the corresponding quarter of the previous year. The net loss widened to ₹499.02 lakhs from ₹371.45 lakhs.
Other Developments
In addition to the ESOP approval and financial results, Trigyn Technologies announced several other key developments:
The Board of Directors approved the roles and responsibilities for Mrs. Bhavana Rao Potluri as Executive Vice Chair, effective immediately.
The company received approval to incorporate a Wholly Owned Subsidiary in Dubai, United Arab Emirates, through its existing wholly owned subsidiary, TTI.
Trigyn Technologies is currently engaged in arbitration proceedings with Nashik Municipal Smart City Development Corporation Ltd (NMSCDCL) following a termination notice issued on September 4, 2023.
The company is facing a show cause cum demand notice from the GST department for ₹9.08 crores, disallowing Input Tax Credit claimed during FY 2019-20 to FY 2022-23.
As Trigyn Technologies navigates these challenges and opportunities, the approval of the ESOP 2025 could serve as a tool to attract and retain talent, which may be crucial for the company's future performance and growth strategies.
Historical Stock Returns for Trigyn Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.49% | -3.61% | -10.61% | -3.95% | -36.38% | +46.00% |





























